ELVN insider ownership: who sold, why, and what they still hold

What stands out

Outside holder ORBIMED ADVISORS LLC, a 10% owner and not part of management, sold $51.7M of stock.Largest sale, Jun 22, 2026

A share of stake is shown for 0 of the 9 officers and directors who sold. 13 are left out

Left out: Joseph Lyssikatos, Samuel Kintz, Anish Patel, Richard Heyman, Lori Kunkel, Benjamin Hohl, Rahul Ballal, Helen Collins, Mika Derynck, Jake Bauer, Rishi Gupta, Richard Fair and Scott Garland (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

Mika Derynck

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$9.6MDisclosed plan

Helen Collins

Chief Medical Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$5.4MDisclosed plan

Joseph Lyssikatos

Chief Scientific Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$4.8MDisclosed plan

Anish Patel

Chief Operating Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$1.6MDisclosed plan

Benjamin Hohl

Chief Financial Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$1.5M81% planned 19% no plan disclosed

All 9 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planNo plan disclosedOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 17, 2026 to Oct 16, 2026

Oct 1, 2026Scott Garland sold 13K shares ($607K) with no plan disclosed. 13K shares came in from vesting or option exercises the same day, so the holding rose by 0 net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Scott Garland Director	13,000	$46.67	n/a	n/a	Oct 1, 2026	Oct 5, 2026

Sep 17, 20262 executives sold 11K shares ($555K) under a disclosed trading plan. 9K shares came in from vesting or option exercises the same day, so their combined holdings fell by 2K net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Benjamin Hohl Chief Financial Officer	6,018	$50.35	n/a	n/a	Sep 17, 2026	Sep 21, 2026
Helen Collins Chief Medical Officer	5,000	$50.35	n/a	n/a	Sep 17, 2026	Sep 21, 2026

"% of total stake" is the shares in an event against all the vested shares the person held that day, across every share class and holding entity, after that day's vesting. "n/a" means the person's holdings are not confirmed, or the row is a purchase. "Holdings record incomplete" means more shares were sold than the filings show the person held that day, so a percentage would be wrong.

Outside holders, reported separately

ORBIMED ADVISORS LLC sold $51.7M in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.

Details

Common questions

Is the Enliven Therapeutics, Inc. CEO selling stock?

Yes. Samuel Kintz sold 25K shares ($539K) in the past 12 months, all of it under a trading plan disclosed in the filings.

Why are Enliven Therapeutics, Inc. insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 96% of sales by value ran under 10b5-1 trading plans disclosed in the filings and 4% had no disclosed plan. A trading plan schedules sales in advance.

Are any Enliven Therapeutics, Inc. insiders buying?

No. Officers and directors reported no purchases in the past 12 months.

The evidence

Who sold9 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Mika Derynck Director	$9.6M 159K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Helen Collins Chief Medical Officer	$5.4M 160K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Joseph Lyssikatos Chief Scientific Officer	$4.8M 188K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Anish Patel Chief Operating Officer	$1.6M 62K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Benjamin Hohl Chief Financial Officer	$1.5M 34K shares	Not confirmed share of stake is being verified. Why	81% under a disclosed plan 19% no plan disclosed
Lori Kunkel Director	$850K 20K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Scott Garland Director	$607K 13K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Samuel Kintz President and CEO, Director	$539K 25K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Richard Heyman Director	$413K 16K shares	Not confirmed share of stake is being verified. Why	Disclosed plan

Board members representing outside shareholders, reported separately: Rishi Gupta. Details

Outside holder, reported separately: ORBIMED ADVISORS LLC (a 10% owner, not part of management). Sold $51.7M (1.14M shares) from Jun 15, 2026 to Jun 22, 2026. Latest filing

The full ownership picture0 of 13 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 16, 2025

Sold

Held Oct 16, 2026

Still held

Joseph Lyssikatos

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Joseph Lyssikatos are complete.

Chief Scientific Officer

n/a

−188K

n/a

Vesting, gifts, unvested awards and holding lines for Joseph Lyssikatos

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Joseph Lyssikatos are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
206,550	$1.12	Jun 15, 2030	$9.4M
185,000	$14.85	Feb 12, 2034	$5.9M
171,000	$22.47	Feb 6, 2035	$4.1M
112,500	$27.16	Feb 12, 2036	$2.2M

Estimate: options held × ($46.67 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Samuel Kintz

President and CEO, Director

n/a

−25K

n/a

Vesting, gifts, unvested awards and holding lines for Samuel Kintz

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Samuel Kintz are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
188,841	$1.12	Jun 15, 2030	$8.6M
410,000	$14.85	Feb 12, 2034	$13.0M
490,000	$22.47	Feb 6, 2035	$11.9M

Estimate: options held × ($46.67 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Anish Patel

Chief Operating Officer

n/a

−62K

n/a

Vesting, gifts, unvested awards and holding lines for Anish Patel

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Anish Patel are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
67	$1.12	Jun 15, 2030	$3K
827	$2.48	Mar 24, 2031	$37K
44,342	$2.48	Mar 24, 2031	$2.0M
185,000	$14.85	Feb 12, 2034	$5.9M
171,000	$22.47	Feb 6, 2035	$4.1M
120,000	$27.16	Feb 12, 2036	$2.3M

Estimate: options held × ($46.67 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Richard Heyman

Director

n/a

−16K

n/a

Vesting, gifts, unvested awards and holding lines for Richard Heyman

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Richard Heyman are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
29,205	$14.85	Feb 13, 2034	$929K
23,014	$22.47	Feb 6, 2035	$557K
19,234	$27.16	Feb 12, 2036	$375K

Estimate: options held × ($46.67 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Lori Kunkel

Director

n/a

−20K

n/a

Vesting, gifts, unvested awards and holding lines for Lori Kunkel

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Lori Kunkel are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
3,741	$1.12	Jun 16, 2030	$170K
37,882	$18.30	Apr 8, 2034	$1.1M
15,368	$22.47	Feb 6, 2035	$372K
17,126	$27.16	Feb 12, 2036	$334K

Estimate: options held × ($46.67 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Benjamin Hohl

Chief Financial Officer

n/a

−34K

n/a

Vesting, gifts, unvested awards and holding lines for Benjamin Hohl

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Benjamin Hohl are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
249,120	$2.48	Aug 2, 2031	$11.0M
155,556	$2.48	Aug 2, 2031	$6.9M
181,018	$14.85	Feb 12, 2034	$5.8M
164,306	$2.48	Aug 2, 2031	$7.3M
84,966	$2.48	Aug 2, 2031	$3.8M
171,000	$22.47	Feb 6, 2035	$4.1M
150,000	$27.16	Feb 12, 2036	$2.9M

Estimate: options held × ($46.67 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Rahul Ballal

Director

n/a

Vesting, gifts, unvested awards and holding lines for Rahul Ballal

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Rahul Ballal are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
69,428	$19.68	May 15, 2029	$1.9M
23,364	$14.85	Feb 13, 2034	$743K
12,322	$5.52	Jan 27, 2032	$507K
20,491	$22.47	Feb 6, 2035	$496K
17,126	$27.16	Feb 12, 2036	$334K

Estimate: options held × ($46.67 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Helen Collins

Chief Medical Officer

n/a

−160K

n/a

Vesting, gifts, unvested awards and holding lines for Helen Collins

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Helen Collins are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
185,000	$14.85	Feb 12, 2034	$5.9M
106,268	$2.48	Jun 17, 2031	$4.7M
171,000	$22.47	Feb 6, 2035	$4.1M
150,000	$27.16	Feb 12, 2036	$2.9M

Estimate: options held × ($46.67 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Mika Derynck

Director

n/a

−159K

n/a

Vesting, gifts, unvested awards and holding lines for Mika Derynck

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Mika Derynck are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
17,126	$27.16	Feb 12, 2036	$334K

Estimate: options held × ($46.67 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Jake Bauer

Director

n/a

Vesting, gifts, unvested awards and holding lines for Jake Bauer

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jake Bauer are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
23,364	$14.85	Feb 13, 2034	$743K
20,491	$22.47	Feb 6, 2035	$496K
17,126	$27.16	Feb 12, 2036	$334K

Estimate: options held × ($46.67 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Rishi Gupta

Director

n/a

Vesting, gifts, unvested awards and holding lines for Rishi Gupta

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Rishi Gupta are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
23,364	$14.85	Feb 13, 2034	$743K
20,491	$22.47	Feb 6, 2035	$496K
33,989	$27.16	Feb 12, 2036	$663K
1,580	$27.16	Feb 12, 2036	$31K

Estimate: options held × ($46.67 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Richard Fair

President and CEO, Director

n/a

Vesting, gifts, unvested awards and holding lines for Richard Fair

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Richard Fair are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
875,000	$18.77	Dec 11, 2035	$24.4M

Estimate: options held × ($46.67 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Scott Garland

Director

n/a

−13K

n/a

Vesting, gifts, unvested awards and holding lines for Scott Garland

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Scott Garland are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
13,072	$24.12	Sep 26, 2034	$295K
13,508	$22.47	Feb 6, 2035	$327K
46,372	$15.47	Jan 7, 2036	$1.4M
1,427	$27.16	Feb 12, 2036	$28K

Estimate: options held × ($46.67 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Holdings and share of stake for Enliven Therapeutics, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$25.3M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $25.3M across 676,377 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $24.4M · 96%

The lighter segment is sales with no plan disclosed in the filing ($903K), including tax-related sales outside a plan.

No plan disclosed · $903K

Sales with no 10b5-1 plan and no tax reference in the filing. $607K of it is Scott Garland. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: Scott Garland, Oct 1, 2026

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Mika Derynck Director	159K	$9.6M	100%	38%	Aug 4, 2026 to Aug 4, 2026
Helen Collins Chief Medical Officer	160K	$5.4M	100%	21%	Feb 17, 2026 to Sep 17, 2026
Joseph Lyssikatos Chief Scientific Officer	188K	$4.8M	100%	19%	Oct 20, 2025 to Feb 6, 2026
Anish Patel Chief Operating Officer	62K	$1.6M	100%	6%	Nov 7, 2025 to Jan 9, 2026
Benjamin Hohl Chief Financial Officer	34K	$1.5M	81%	6%	Mar 6, 2026 to Sep 17, 2026
Lori Kunkel Director	20K	$850K	100%	3%	Jun 5, 2026 to Jul 6, 2026
Scott Garland Director	13K	$607K	0%	2%	Oct 1, 2026 to Oct 1, 2026
Samuel Kintz President and CEO, Director	25K	$539K	100%	2%	Oct 17, 2025 to Nov 17, 2025
Richard Heyman Director	16K	$413K	100%	2%	Jan 8, 2026 to Feb 17, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$543K	$543K	$0	$0
Nov 2025	$668K	$668K	$0	$0
Dec 2025	$224K	$224K	$0	$0
Jan 2026	$5.7M	$5.7M	$0	$0
Feb 2026	$1.4M	$1.4M	$0	$0
Mar 2026	$3.0M	$2.7M	$0	$296K
Apr 2026	$238K	$238K	$0	$0
May 2026	$199K	$199K	$0	$0
Jun 2026	$828K	$828K	$0	$0
Jul 2026	$1.1M	$1.1M	$0	$0
Aug 2026	$10.2M	$10.2M	$0	$0
Sep 2026	$555K	$555K	$0	$0
Oct 2026	$607K	$0	$0	$607K

Board members representing outside shareholders (1)Listed and sourced; not part of the management totals or the answer line

Directors whose reported holdings sit mostly in an investment fund or a corporate shareholder they represent, not in their own name, with beneficial ownership disclaimed except for their own financial interest. Listed and sourced here; not part of the management totals or the answer line. Shares a fund hands to its own investors are distributions, not sales.

Board member	Held Oct 16, 2025	Sold	Held Oct 16, 2026	Still held
Rishi Gupta ! Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Rishi Gupta are complete. Director	n/a	0	n/a	n/a
Vesting, gifts, unvested awards and holding lines for Rishi Gupta Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Rishi Gupta are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts)

Is this normal? Selling year by year5 earlier years to compare with

More than usual: $25.3M sold, after almost none in the past 5 years. 9 insiders sold; the average is 4 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 16, 2026 Latest 12 months	676K	9	$25.3M
Oct 16, 2025 1 year earlier	321K	6	$6.7M
Oct 16, 2024 2 years earlier	791K	7	$17.5M
Oct 17, 2023 3 years earlier	38K	4	$587K
Oct 17, 2022 4 years earlier	0	0	$0
Oct 17, 2021 5 years earlier	1.6K	2	$156K

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty13 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Enliven Therapeutics, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology377 filings on record, 52 filed in the 12-month period, and how we read them

All 377 Forms 3, 4 and 5 on record for Enliven Therapeutics, Inc. (SEC CIK 1672619), filed from Mar 11, 2020 to Oct 5, 2026; 52 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 16, 2026. Prices are the ones reported in each filing, often weighted averages.

Probable 1-for-4 stock split on or before Feb 23, 2023 (split date stated in a footnote). Splits aren't reported as transactions; 3 holding lines changed by exactly this ratio, so earlier share counts are restated.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (29)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
Andrew Phillips	Feb 10, 2025	No balance on record
5AM Partners VI, LLC	Feb 16, 2024	3,835,975 shares, last reported balance as of Feb 14, 2024
Andrew Schwab	Apr 6, 2023	No balance on record
Andrew Schwab	Apr 6, 2023	5,798,475 shares, last reported balance as of Feb 23, 2023
RA CAPITAL MANAGEMENT, L.P.	Feb 27, 2023	3,298,733 shares, last reported balance as of Feb 23, 2023
COMMODORE CAPITAL LP	Feb 27, 2023	1,448,640 shares, last reported balance as of Feb 23, 2023
Michael Gray	Feb 22, 2023	6,903 shares, last reported balance as of Feb 22, 2023
Braden Leonard	Jan 5, 2023	499,444 shares, last reported balance as of Jan 4, 2023
David Bonita	Jun 3, 2022	No balance on record
Carl Goldfischer	Jun 3, 2022	175,845 shares, last reported balance as of Jun 2, 2022
Mark Chin	Jun 3, 2022	586,018 shares, last reported balance as of Jun 2, 2022
Barbara Dalton	Jun 3, 2022	389,431 shares, last reported balance as of Jun 2, 2022
David Mott	Jun 3, 2022	57,306 shares, last reported balance as of Jun 2, 2022
Edward Conner	Jun 3, 2022	No balance on record
Laura Williams	Jun 3, 2022	No balance on record
David Bonita	Jun 3, 2022	1,049,767 shares, last reported balance as of Jun 2, 2022
Carl Goldfischer	Jun 3, 2022	No balance on record
New Enterprise Associates 14, L.P.	Apr 7, 2022	652,763 shares, last reported balance as of Apr 6, 2022
Kenneth Attie	Feb 1, 2022	8,525 shares, last reported balance as of Jan 28, 2022
Sara Nayeem	Jun 30, 2021	No balance on record
Alexandria Venture Investments, LLC	Mar 16, 2020	73,253 shares, last reported balance as of Mar 16, 2020
Mette Agger	Mar 16, 2020	358,181 shares, last reported balance as of Mar 16, 2020
Arix Bioscience plc	Mar 16, 2020	388,640 shares, last reported balance as of Mar 16, 2020
Lundbeck H	Mar 16, 2020	130,625 shares, last reported balance as of Mar 16, 2020
James McArthur	Mar 16, 2020	109 shares, last reported balance as of Mar 11, 2020
Rock Springs Capital Management LP	Mar 16, 2020	130,853 shares, last reported balance as of Mar 16, 2020
PFIZER INC	Mar 16, 2020	389,431 shares, last reported balance as of Mar 16, 2020
Christoph Adams	Mar 11, 2020	20,941 shares, last reported balance as of Mar 11, 2020
Willem Scheele	Mar 11, 2020	No balance on record

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

Enliven Therapeutics, Inc. insiders sold $25.3M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Outside holders, reported separately

Common questions

Is the Enliven Therapeutics, Inc. CEO selling stock?

Why are Enliven Therapeutics, Inc. insiders selling?

Are any Enliven Therapeutics, Inc. insiders buying?

The evidence

No plan disclosed · $903K

Sales by month